177 related articles for article (PubMed ID: 22102168)
1. Newcastle disease virus induces pro-inflammatory conditions and type I interferon for counter-acting Treg activity.
Fournier P; Arnold A; Wilden H; Schirrmacher V
Int J Oncol; 2012 Mar; 40(3):840-50. PubMed ID: 22102168
[TBL] [Abstract][Full Text] [Related]
2. Importance of retinoic acid-inducible gene I and of receptor for type I interferon for cellular resistance to infection by Newcastle disease virus.
Fournier P; Wilden H; Schirrmacher V
Int J Oncol; 2012 Jan; 40(1):287-98. PubMed ID: 21971670
[TBL] [Abstract][Full Text] [Related]
3. MAVS-dependent IRF3/7 bypass of interferon β-induction restricts the response to measles infection in CD150Tg mouse bone marrow-derived dendritic cells.
Takaki H; Honda K; Atarashi K; Kobayashi F; Ebihara T; Oshiumi H; Matsumoto M; Shingai M; Seya T
Mol Immunol; 2014 Feb; 57(2):100-10. PubMed ID: 24096085
[TBL] [Abstract][Full Text] [Related]
4. Cell-type-specific innate immune response to oncolytic Newcastle disease virus.
Biswas M; Kumar SR; Allen A; Yong W; Nimmanapalli R; Samal SK; Elankumaran S
Viral Immunol; 2012 Aug; 25(4):268-76. PubMed ID: 22808996
[TBL] [Abstract][Full Text] [Related]
5. Type I interferon-sensitive recombinant newcastle disease virus for oncolytic virotherapy.
Elankumaran S; Chavan V; Qiao D; Shobana R; Moorkanat G; Biswas M; Samal SK
J Virol; 2010 Apr; 84(8):3835-44. PubMed ID: 20147405
[TBL] [Abstract][Full Text] [Related]
6. Analysis of three properties of Newcastle disease virus for fighting cancer: tumor-selective replication, antitumor cytotoxicity, and immunostimulation.
Fournier P; Bian H; Szeberényi J; Schirrmacher V
Methods Mol Biol; 2012; 797():177-204. PubMed ID: 21948477
[TBL] [Abstract][Full Text] [Related]
7. Signaling through RIG-I and type I interferon receptor: Immune activation by Newcastle disease virus in man versus immune evasion by Ebola virus (Review).
Schirrmacher V
Int J Mol Med; 2015 Jul; 36(1):3-10. PubMed ID: 25998621
[TBL] [Abstract][Full Text] [Related]
8. Important role of interferon regulatory factor (IRF)-3 in the interferon response of mouse macrophages upon infection by Newcastle disease virus.
Wilden H; Schirrmacher V; Fournier P
Int J Oncol; 2011 Aug; 39(2):493-504. PubMed ID: 21567079
[TBL] [Abstract][Full Text] [Related]
9. Selective oncolytic effect of an attenuated Newcastle disease virus (NDV-HUJ) in lung tumors.
Yaacov B; Eliahoo E; Lazar I; Ben-Shlomo M; Greenbaum I; Panet A; Zakay-Rones Z
Cancer Gene Ther; 2008 Dec; 15(12):795-807. PubMed ID: 18535620
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of the alpha/beta interferon response by mouse hepatitis virus at multiple levels.
Roth-Cross JK; Martínez-Sobrido L; Scott EP; García-Sastre A; Weiss SR
J Virol; 2007 Jul; 81(13):7189-99. PubMed ID: 17459917
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of Newcastle disease virus mediated dendritic cell activation and cross-priming tumor-specific immune responses ex vivo.
Xu Q; Rangaswamy US; Wang W; Robbins SH; Harper J; Jin H; Cheng X
Int J Cancer; 2020 Jan; 146(2):531-541. PubMed ID: 31584185
[TBL] [Abstract][Full Text] [Related]
12. Oncolytic Newcastle disease virus as a prospective anti-cancer therapy. A biologic agent with potential to break therapy resistance.
Schirrmacher V
Expert Opin Biol Ther; 2015; 15(12):1757-71. PubMed ID: 26436571
[TBL] [Abstract][Full Text] [Related]
13. Cell type-specific involvement of RIG-I in antiviral response.
Kato H; Sato S; Yoneyama M; Yamamoto M; Uematsu S; Matsui K; Tsujimura T; Takeda K; Fujita T; Takeuchi O; Akira S
Immunity; 2005 Jul; 23(1):19-28. PubMed ID: 16039576
[TBL] [Abstract][Full Text] [Related]
14. The IFN regulatory factor 7-dependent type I IFN response is not essential for early resistance against murine cytomegalovirus infection.
Steinberg C; Eisenächer K; Gross O; Reindl W; Schmitz F; Ruland J; Krug A
Eur J Immunol; 2009 Apr; 39(4):1007-18. PubMed ID: 19283778
[TBL] [Abstract][Full Text] [Related]
15. Ebolavirus VP35 suppresses IFN production from conventional but not plasmacytoid dendritic cells.
Leung LW; Park MS; Martinez O; Valmas C; López CB; Basler CF
Immunol Cell Biol; 2011 Oct; 89(7):792-802. PubMed ID: 21263462
[TBL] [Abstract][Full Text] [Related]
16. Expression of RIG-I, IRF3, IFN-beta and IRF7 determines resistance or susceptibility of cells to infection by Newcastle Disease Virus.
Wilden H; Fournier P; Zawatzky R; Schirrmacher V
Int J Oncol; 2009 Apr; 34(4):971-82. PubMed ID: 19287954
[TBL] [Abstract][Full Text] [Related]
17. Persistent Newcastle disease virus infection in bladder cancer cells is associated with putative pro-survival and anti-viral transcriptomic changes.
Chan LC; Kalyanasundram J; Leong SW; Masarudin MJ; Veerakumarasivam A; Yusoff K; Chan SC; Chia SL
BMC Cancer; 2021 May; 21(1):625. PubMed ID: 34044804
[TBL] [Abstract][Full Text] [Related]
18. Recombinant Newcastle disease virus (NDV) with inserted gene coding for GM-CSF as a new vector for cancer immunogene therapy.
Janke M; Peeters B; de Leeuw O; Moorman R; Arnold A; Fournier P; Schirrmacher V
Gene Ther; 2007 Dec; 14(23):1639-49. PubMed ID: 17914407
[TBL] [Abstract][Full Text] [Related]
19. IRF-3, IRF-5, and IRF-7 coordinately regulate the type I IFN response in myeloid dendritic cells downstream of MAVS signaling.
Lazear HM; Lancaster A; Wilkins C; Suthar MS; Huang A; Vick SC; Clepper L; Thackray L; Brassil MM; Virgin HW; Nikolich-Zugich J; Moses AV; Gale M; Früh K; Diamond MS
PLoS Pathog; 2013 Jan; 9(1):e1003118. PubMed ID: 23300459
[TBL] [Abstract][Full Text] [Related]
20. Construction of recombinant Newcastle disease virus Italien strain for oncolytic virotherapy of tumors.
Wei D; Sun N; Nan G; Wang Y; Liu HQ; Peeters B; Chen ZN; Bian H
Hum Gene Ther; 2012 Jul; 23(7):700-10. PubMed ID: 22372930
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
